the case for selection at ccr5-δ32在ccr5-δ32选择的理由.pdfVIP

Open access, freely available online PLoS BIOLOGY The Case for Selection at CCR5-D32 1,2* 1 1 1 1 3 3 Pardis C. Sabeti , Emily Walsh , Steve F. Schaffner , Patrick Varilly , Ben Fry , Holli B. Hutcheson , Mike Cullen , Tarjei S. Mikkelsen1 1 1 4 1,5 1,5,6 , Jessica Roy , Nick Patterson , Richard Cooper , David Reich , David Altshuler , Stephen O’Brien3, Eric S. Lander1,7,8,9 1 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America, 2 Harvard Medical School, Boston, Massachusetts, United States of America, 3 Laboratory of Genomic Diversity, National Cancer Institute, Frederick, Maryland, United States of America, 4 Department of Preventive Medicine and Epidemiology, Loyola University Medical School, Maywood, Illinois, United States of America, 5 Departments of Genetics and Medicine, Harvard Medical School, Boston, Massachusetts, United States of America, 6 Department of Molecular Biology and Center for Human Genetic Research, Diabetes Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 7 Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America, 8 Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, United States of America, 9 Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, United States of America The C-C chemokine receptor 5, 32 base-pair deletion (CCR5-D32) allele confers strong resistance to infection by the AIDS virus HIV. Previous studies ha